Poteligeo (Mogamulizumab) is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody used to treat adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.
Dosage: The recommended dose of Poteligeo injection is 1 mg/kg. It should be administered as an intravenous infusion over minimum an hour. Administer on days 1’st, 8’th, 15’th, and 22’nd of the first 28-day cycle, then on days 1’st and 15’th of each subsequent 28-day cycle until the disease is progressive or observes any unacceptable toxicity. Take mogamulizumab within two days of the scheduled dose. In case a dose is missed, take the next dose promptly and resume the dosing schedule. Avoid taking it subcutaneously or by rapid intravenous administration.
Side Effects: The most commonly reported mogamulizumab side effects may include:
- Infusion related reactions
- Musculoskeletal pain
- Upper respiratory tract infection
Warnings and Precautions:
- Patients with poteligeo dosage should be monitored for rash throughout the treatment course.
- Patients while on poteligeo treatment are recommended to be monitored for the signs/symptoms of infection and must be treated promptly.
- Patients receiving poteligeo injection therapy should be closely monitored for signs/symptoms of the infusion reactions and the infusion should be interrupted for any grade reaction.
- Use of mogamulizumab injection should be avoided during pregnancy or in those females of childbearing age who are not considering contraception.
- Females of reproductive age should be verified pregnancy status prior to strat the with mogamulizumab-kpkc.